John W. LaRocca
2021
Compensation breakdown
Non-Equity Incentive Plan | $217,522 |
---|---|
Option Awards | $583,631 |
Salary | $451,760 |
Stock Awards | $194,040 |
Other | $7,342 |
Total | $1,454,295 |
LaRocca received $583.6K in option awards, accounting for 40% of the total pay in 2021.
LaRocca also received $217.5K in non-equity incentive plan, $451.8K in salary, $194K in stock awards and $7.3K in other compensation.
Rankings
In 2021, John W. LaRocca's compensation ranked 7,384th out of 12,415 executives tracked by ExecPay. In other words, LaRocca earned more than 40.5% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 7,384 | 41st |
Manufacturing | 3,245 | 41st |
Chemicals And Allied Products | 1,437 | 40th |
Drugs | 1,280 | 39th |
Biological Products, Except Diagnostic Substances | 295 | 34th |
LaRocca's colleagues
We found seven more compensation records of executives who worked with John W. LaRocca at Aerie Pharmaceuticals in 2021.
2021
Vicente Anido
Aerie Pharmaceuticals
Chief Executive Officer
2021
Raj Kannan
Aerie Pharmaceuticals
Chief Executive Officer
2021
Thomas Mitro
Aerie Pharmaceuticals
Chief Operating Officer
2021
Casey Kopczynski
Aerie Pharmaceuticals
Chief Innovation Officer, Head of Research and External Innovation
2021
Benjamin McGraw
Aerie Pharmaceuticals
Former Interim Executive Chair
2021
Richard Rubino
Aerie Pharmaceuticals
Chief Financial Officer
2021
Christopher Staten
Aerie Pharmaceuticals
Chief Financial Officer
News
April 26, 2022
April 27, 2021
April 24, 2020
April 10, 2019